The Lancet calls on drugs industry to fund more "personalised" cancer trials
This article was originally published in Scrip
In an editorial entitled, "Cancer: the revolution has begun," The Lancet has called on the pharmaceutical industry to more often fund clinical trials that stratify cancer patients by known or potential biomarkers. And while many recently completed and ongoing industry-sponsored Phase III trials have not in fact been stratified, leading cancer drug developers assert that "personalised medicine" is in fact their focus.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.